How many 8-K filings has Trisalus Life Sciences, Inc. filed?

Trisalus Life Sciences, Inc. (TLSIW) has 29 8-K (Current Event Report) filings on record, spanning Jan 2024 to Oct 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Trisalus Life Sciences, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Trisalus Life Sciences, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Trisalus Life Sciences, Inc. (TLSIW) — 8-K Filings

All 8-K filings from Trisalus Life Sciences, Inc.. Browse 29 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (29)

TriSalus Life Sciences Announces Board and Officer Changes — Oct 1, 2025 Risk: medium
TriSalus Life Sciences, Inc. filed an 8-K on October 1, 2025, reporting changes effective September 30, 2025. The filing details the departure of directors, ele
TriSalus Life Sciences Announces Board and Officer Changes — Aug 29, 2025 Risk: medium
TriSalus Life Sciences, Inc. announced on August 25, 2025, changes in its board of directors and officer appointments. The filing details the departure of certa
TriSalus Life Sciences Files 8-K on Security Holder Rights & Bylaws — Jul 24, 2025 Risk: medium
On July 24, 2025, TriSalus Life Sciences, Inc. filed an 8-K report detailing several key events. The company announced material modifications to the rights of i
TriSalus Life Sciences Files 8-K — Jun 23, 2025 Risk: low
On June 23, 2025, TriSalus Life Sciences, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update
TriSalus Life Sciences Reports on Shareholder Vote — Jun 16, 2025 Risk: low
TriSalus Life Sciences, Inc. filed an 8-K on June 16, 2025, reporting on matters submitted to a vote of security holders on June 12, 2025. The filing pertains t
TriSalus Life Sciences Files 8-K with Key Updates — Apr 30, 2025 Risk: medium
TriSalus Life Sciences, Inc. filed an 8-K on April 30, 2025, reporting on a material definitive agreement, results of operations, unregistered sales of equity s
TriSalus Life Sciences Announces Board and Executive Changes — Apr 23, 2025 Risk: medium
TriSalus Life Sciences, Inc. announced on April 20, 2025, changes in its board of directors and executive compensation. Specifically, the company elected new di
TriSalus Life Sciences Appoints New CMO, Director — Apr 17, 2025 Risk: medium
TriSalus Life Sciences, Inc. announced on April 16, 2025, the appointment of Dr. David L. Smith as Chief Medical Officer and the election of Ms. Jennifer L. Smi
TriSalus Life Sciences Files 8-K on Financials — Mar 27, 2025 Risk: low
TriSalus Life Sciences, Inc. filed an 8-K on March 27, 2025, reporting on its results of operations and financial condition, and filing financial statements and
TriSalus Life Sciences Appoints New CMO, Director — Feb 25, 2025 Risk: medium
TriSalus Life Sciences, Inc. announced on February 19, 2025, the appointment of Dr. David L. Smith as Chief Medical Officer and the election of Ms. Jennifer L.
TriSalus Life Sciences Reports Financial Obligation & Equity Sale — Feb 19, 2025 Risk: medium
On February 18, 2025, TriSalus Life Sciences, Inc. filed an 8-K detailing two key events. First, the company entered into a direct financial obligation. Second,
TriSalus Life Sciences Files 8-K on Financials — Feb 3, 2025 Risk: low
TriSalus Life Sciences, Inc. filed an 8-K on February 3, 2025, reporting on its financial condition and results of operations as of January 31, 2025. The filing
TriSalus Life Sciences Announces Executive and Board Changes — Jan 31, 2025 Risk: medium
TriSalus Life Sciences, Inc. announced on January 29, 2025, a series of executive and board changes. Dr. Michael J. McGarrity has been appointed as Chief Medica
TriSalus Life Sciences Files 8-K on Financials — Jan 23, 2025 Risk: low
TriSalus Life Sciences, Inc. filed an 8-K on January 23, 2025, reporting on its results of operations and financial condition. The filing includes financial sta
TriSalus Life Sciences Files 8-K on Officer/Director Changes — Jan 8, 2025 Risk: medium
TriSalus Life Sciences, Inc. filed an 8-K on January 8, 2025, reporting events as of January 4, 2025. The filing pertains to the departure of directors or certa
TriSalus Life Sciences Files 8-K — Nov 14, 2024 Risk: low
TriSalus Life Sciences, Inc. filed an 8-K on November 14, 2024, reporting on its results of operations and financial condition. The filing includes financial st
TriSalus Life Sciences Board Changes — Nov 1, 2024 Risk: medium
TriSalus Life Sciences, Inc. announced on October 28, 2024, a change in its board of directors. Specifically, the company reported the departure of Director Dav
TriSalus Life Sciences Files 8-K on Operations and Shareholder Votes — Aug 15, 2024 Risk: low
TriSalus Life Sciences, Inc. filed an 8-K on August 15, 2024, reporting on matters including results of operations, financial condition, and submission of matte
TriSalus Life Sciences Files 8-K — Jul 1, 2024 Risk: low
TriSalus Life Sciences, Inc. filed an 8-K on July 1, 2024, reporting other events and financial statements. The company, formerly known as MedTech Acquisition C
TriSalus Life Sciences Enters Material Agreement — Jun 27, 2024 Risk: medium
TriSalus Life Sciences, Inc. announced on June 26, 2024, that it entered into a material definitive agreement. The company also submitted matters to a vote of i
TriSalus Life Sciences Files 8-K — May 24, 2024 Risk: low
TriSalus Life Sciences, Inc. filed an 8-K on May 24, 2024, reporting other events and financial statements. The company, formerly known as MedTech Acquisition C
TriSalus Life Sciences Files 8-K on Financials — May 15, 2024 Risk: low
TriSalus Life Sciences, Inc. filed an 8-K on May 15, 2024, reporting on its results of operations and financial condition. The filing includes financial stateme
TriSalus Life Sciences Appoints New CMO, Director — May 7, 2024 Risk: medium
TriSalus Life Sciences, Inc. announced on May 7, 2024, the appointment of Dr. David L. R. Smith as Chief Medical Officer and the election of Ms. Jennifer L. Jon
TriSalus Life Sciences Files 8-K with Material Agreements — Apr 30, 2024 Risk: medium
On April 30, 2024, TriSalus Life Sciences, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reported
TriSalus Life Sciences Appoints New Auditor — Apr 16, 2024 Risk: low
TriSalus Life Sciences, Inc. announced on April 12, 2024, that it has appointed PricewaterhouseCoopers LLP as its new independent registered public accounting f
TriSalus Life Sciences Files 8-K on Financials — Apr 1, 2024 Risk: low
TriSalus Life Sciences, Inc. filed an 8-K on April 1, 2024, reporting on its results of operations and financial condition. The filing also includes financial s
TriSalus Life Sciences to Acquire Fusion Medical for $15M — Mar 12, 2024 Risk: medium
TriSalus Life Sciences, Inc. announced on March 11, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests of Fusion
TriSalus Life Sciences Files 8-K on Jan 24 Event — Jan 25, 2024
TriSalus Life Sciences, Inc. filed an 8-K on January 25, 2024, reporting an event that occurred on January 24, 2024. This filing is a 'Current Report' under Sec
TriSalus 8-K Signals Active Communications Under Securities Rules — Jan 5, 2024
TriSalus Life Sciences, Inc. filed an 8-K on January 5, 2024, indicating it is satisfying filing obligations related to written communications under Rule 425 of

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX